Does cryopreservation of embryos increase risk of placenta accreta?
A small study by investigators from Harvard University suggests that cryopreserved embryo transfer (CET) is a strong independent risk factor for placenta accreta in women undergoing in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI).
A small study by investigators from Harvard University suggests that cryopreserved embryo transfer (CET) is a strong independent risk factor for placenta accreta in women undergoing in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI). The findings, presented at the American Society for Reproductive Medicine 70th Annual Meeting, showed an even stronger association in cases of accreta with complications.
Data on 1,569 women who had delivered at least one viable infant at ≥24 weeks’ gestation and underwent a Day 3 or Day 5 transfer at a single institution between 2005 and 2011 were included in the analysis. Among them, 52 cases of placenta accreta were identified, as confirmed by histology or a clinical finding of an adherent placenta with or without morbid complications such as postpartum hemorrhage, hysterectomy or surgery to remove the placenta. Cases were matched 1:3 by maternal age and history of prior cesarean to IVF/ICSI patients without accreta.
Multivariate analysis resulted in an overall incidence of accreta in the cohort of 3.31% (52/1,569), versus 7.24% (16/221) in the women who had undergone CET. The median age of cases and controls was similar (39.3 versus 39.1). No potential confounders were included in the final model because none were found to change the effect size for CET by more than 10%.
Feature: Euploid single-embryo transfer: The new IVF paradigm
The only significant predictors of accreta were CET (P=.04), prior myomectomy (P<.01), and placenta previa (P<.0001). When the analysis was restricted to only morbid cases of accreta, the effect was strengthened to 2.78 (95% CI 1.11-6.99; P=.03).
To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary OB/GYN Special Delivery.
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Link between reproductive life span and postmenopausal muscle mass
November 30th 2023A recent study in Menopause, the journal of The Menopause Society, suggests that a longer reproductive life span and later age at menopause may be associated with a reduced risk of low handgrip strength in postmenopausal women.
Read More
How physicians can boost COVID-19 vaccine uptake among Spanish-speaking pregnant individuals
November 29th 2023Discover the crucial findings from a recent study investigating vaccine decision-making among Spanish-speaking pregnant individuals, highlighting the pivotal role doctors play in dispelling vaccine hesitancy and fostering acceptance through targeted information dissemination and culturally sensitive approaches.
Read More
NIDA study reports surge in pregnancy-associated drug overdose deaths
November 29th 2023Researchers from the National Institute on Drug Abuse unveil a 3-fold spike in drug overdose deaths among pregnant women aged 10 to 44 years between 2018 and 2021, highlighting pervasive barriers like discrimination and stigma hindering access to life-saving treatment.
Read More
